Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1 - PubMed (original) (raw)
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1
Gayathri Subramanian et al. Cancer Res. 2004.
Abstract
Transforming growth factor-beta (TGF-beta) suppresses tumor formation by blocking cell cycle progression and maintaining tissue homeostasis. In pancreatic carcinomas, this tumor suppressive activity is often lost by inactivation of the TGF-beta-signaling mediator, Smad4. We found that human pancreatic carcinoma cell lines that have undergone deletion of MADH4 constitutively expressed high endogenous levels of phosphorylated receptor-associated Smad proteins (pR-Smad2 and pR-Smad3), whereas Smad4-positive lines did not. These elevated pR-Smad levels could not be attributed to a decreased dephosphorylation rate nor to increased expression of TGF-beta type I (TbetaR-I) or type II (TbetaR-II) receptors. Although minimal amounts of free bioactive TGF-beta1 and TGF-beta2 were detected in conditioned medium, treatment with a pan-specific (but not a TGF-beta3 specific) TGF-beta-neutralizing antibody and with anti-alpha(V)beta(6) integrin antibody decreased steady-state pSmad2 levels and activation of a TGF-beta-inducible reporter gene in neighboring cells, respectively. Thus, activation of TGF-beta at the cell surface was responsible for the increased autocrine endogenous and paracrine signaling. Blocking TbetaR-I activity using a selective kinase inhibitor (SD-093) strongly decreased the in vitro motility and invasiveness of the pancreatic carcinoma cells without affecting their growth characteristics, morphology, or the subcellular distribution of E-cadherin and F-actin. Moreover, exogenous TGF-beta strongly stimulated in vitro invasiveness of BxPC-3 cells, an effect that could also be blocked by SD-093. Thus, the motile and invasive properties of Smad4-deficient pancreatic cancer cells are at least partly driven by activation of endogenous TGF-beta signaling. Therefore, targeting the TbetaR-I kinase represents a potentially powerful novel therapeutic approach for the treatment of this disease.
Similar articles
- TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P. Nakao A, et al. EMBO J. 1997 Sep 1;16(17):5353-62. doi: 10.1093/emboj/16.17.5353. EMBO J. 1997. PMID: 9311995 Free PMC article. - Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Horie K, Yamashita H, Mogi A, Takenoshita S, Miyazono K. Horie K, et al. J Cell Physiol. 1998 Jun;175(3):305-13. doi: 10.1002/(SICI)1097-4652(199806)175:3<305::AID-JCP8>3.0.CO;2-S. J Cell Physiol. 1998. PMID: 9572475 - SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. Uhl M, et al. Cancer Res. 2004 Nov 1;64(21):7954-61. doi: 10.1158/0008-5472.CAN-04-1013. Cancer Res. 2004. PMID: 15520202 - The role of TGFbeta in human cancers.
Wong SF, Lai LC. Wong SF, et al. Pathology. 2001 Feb;33(1):85-92. Pathology. 2001. PMID: 11280615 Review. - The Smad family and its role in pancreatic cancer.
Singh P, Wig JD, Srinivasan R. Singh P, et al. Indian J Cancer. 2011 Jul-Sep;48(3):351-60. doi: 10.4103/0019-509X.84939. Indian J Cancer. 2011. PMID: 21921337 Review.
Cited by
- Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE. Yingling JM, et al. Oncotarget. 2017 Dec 31;9(6):6659-6677. doi: 10.18632/oncotarget.23795. eCollection 2018 Jan 23. Oncotarget. 2017. PMID: 29467918 Free PMC article. - Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.
Malek R, Wang H, Taparra K, Tran PT. Malek R, et al. Cells Tissues Organs. 2017;203(2):114-127. doi: 10.1159/000447238. Epub 2017 Feb 20. Cells Tissues Organs. 2017. PMID: 28214899 Free PMC article. Review. - Human Surfactant Protein D Suppresses Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells by Downregulating TGF-β.
Kaur A, Riaz MS, Singh SK, Kishore U. Kaur A, et al. Front Immunol. 2018 Aug 15;9:1844. doi: 10.3389/fimmu.2018.01844. eCollection 2018. Front Immunol. 2018. PMID: 30158928 Free PMC article. - Imbalanced expression of Tif1γ inhibits pancreatic ductal epithelial cell growth.
Ligr M, Wu X, Daniels G, Zhang D, Wang H, Hajdu C, Wang J, Pan R, Pei Z, Zhang L, Melis M, Pincus MR, Saunders JK, Lee P, Xu R. Ligr M, et al. Am J Cancer Res. 2014 May 26;4(3):196-210. eCollection 2014. Am J Cancer Res. 2014. PMID: 24959375 Free PMC article. - Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C, van Ginkel JQ, Kinderman P, Sluijter M, Griffioen L, Labrie C, van den Wollenberg DJM, Hoeben RC, van der Burg SH, Ten Dijke P, Hawinkels LJAC, van Hall T, van Montfoort N. Groeneveldt C, et al. Cancer Res Commun. 2023 Feb 23;3(2):325-337. doi: 10.1158/2767-9764.CRC-23-0019. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36860656 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous